BlossomHill Therapeutics, Inc.: Janus Henderson Group Ltd. discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Janus Henderson Group Ltd. disclosed a stake exceeding 5% in BlossomHill Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001274173-26-000283). The exact share count and percentage were not specified in the filing headline. The disclosure signals a significant institutional position in the clinical-stage oncology company. Investors will watch for further detail on the size and nature of the holding in subsequent filings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
BlossomHill Therapeutics, Inc., Janus Henderson Group Ltd.